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IDENTIFICATION OF AN AUC OF 7603 UMOL*MIN/HR PER DAY X 4 DAYS
AS THE MAXIMUM TOLERATED DOSE (MTD) OF IV CONTINUOUS INFU-
SION (CI) BUSULFAN (BU) WITH FIXED DOSE FLUDARABINE (FLU) IN
A PHARMACOKINETICALLY-BASED DOSE PHASE I STUDY IN PATIENTS
(PTS) WITH HEMATOLOGIC MALIGNANCIES UNDERGOING ALLOGENEIC
STEM CELL TRANSPLANTATION
Wood, W.A., Walko, C.M., Rao, K.V., Whitley, J., Moore, D.T.,
Gabriel, D.A., Serody, J.S., Coghill, J.M., Shea, T.C. University of North
Carolina at Chapel Hill, Chapel Hill, NC
We previously demonstrated the benefit of using a test-dose of IV
Busulfan to predict systemic exposure in patients with hematologic
malignancies undergoing allogeneic stem cell transplant (Walko et
al, J Clin Oncol, ASCO, 24, : 16502, 2006). We now report on
this approach in 30 pts receiving a 90-hrCI of Bu in a dose-escalation
study.
Methods: Pts received a 0.8 mg/kg test dose over 2 hours and PK
sampling at 0, 2.5, 4, 5, and 6 hours one week prior to initiation of
full-dose treatment. Conditioning consisted of 30 mg/m2 Flu qd 
5 and targeted Bu to achieve an AUC of 4800 (9 pts), 5760 (6 pts),
6912 (8 pts), 7603 (3 pts) or 8363 (2 pts) umol*min/hr/d on days
-7 to -3. PK sampling occurred at hours 0, 12, 16, 18, 48, 60, 72,
and 89.5. All pts received tacrolimus and IV alemtuzumab in doses
of 30mg for matched related donors (MRD) or 60mg for matched
unrelated donors (MUD) for prevention of GVHD.
Results: 30 pts (14 MRD, 16 MUD) ages 18–55 (median 37) with
high-risk AML (11), ALL (7), MDS (4), or other (8) were enrolled.
All engrafted with a median of 13 days to ANC i 500 and 14 days
to platelet count i 20Kwith no late graft failures. There were 9 treat-
ment related deaths. Seven were from infection: pneumonia (1) and
biliary sepsis (1) prior to day 100, and aspergillus (2), nocardia (1),
biliary sepsis (1), and hemorrhagic cystitis (1) after day 100. One
death was from late VOD and liver failure (d 201), and one from
leukoencephalopathy (d 196). Grade 4 toxicities included 3 cases of
mucositis (2 at dose level 5, AUC 8363, and 1 at level 2), and 1 liver
failure at level 2. Grade 3 toxicities included mucositis (8), hepatitis
(3) pneumonia (2) and seizures (1). 11 pts developed grade 2, two
grade 3, and one grade 4 aGVHD. Two pts developed extensive
and two developed limited cGVHD. 11 pts (37%) relapsed at a
median of 117 days (range 17–652) post-transplant. PFS at 18
months was 36%. The MTD was level 4 with a target AUC of
7603 umol*min/hr per day 4 days. Dose limiting toxicity was grade
4 mucositis in 2/2 pts at dose level 5 with an actual mean AUC of
8600 umol*min/hr per day  4 days.
Conclusion: This approach permits accurate delivery of a 55%
increase in target systemic exposure to IV Bu compared to the stan-
dard AUC of 4800 umol*min/hr per day x 4 days, is well-tolerated,
and will be studied in a Phase II trial with ATG and MTX as
GVH prophylaxis in an attempt to reduce the rate of deaths from
late infections and relapse.271
A STRATEGY FOR DISTINGUISHING SNP IDENTITY IN MULTIPLE-
DONORS INVOLVED IN HAPLOIDENTICAL BONE MARROW TRANSPLAN-
TATION
Chen, X., Hofmann, T.J., Otsuru, S., Jethva, R., Horwitz, E.M. The
Children’s Hospital of Philadelphia, Philadelphia, PA
Chimerism is an important index in hematopoietic cell transplan-
tation (HCT). Determination of chimerism can be challenging in
cases of multiple-donors, such as second allogeneic HCT, double-
cord blood transplantation, or novel cell therapies. Commonly
used methods used to estimate chimerism include cytogenetic anal-
ysis in sex disparate transplantations and molecular analysis of poly-
morphic tandem repeat sequences; however, these techniques areeither restricted by gender or inefficient sensitivity. Single nucleotide
polymorphisms (SNPs) are the most common source of human
genetic diveristy, providing a virtually unlimited resource of molec-
ular markers that can be used to distinguish individuals. In principle,
real-time PCR-based assays can be used to assess SNPs, and such
assays demonstrate a substantially higher sensitivity (0.001%), but
the specificity is unclear due to a low level signal from mismatched
sequences. In this study, we cloned 14 pairs of SNPs selected from
the SNP HapMap database and examined the specificity and sensi-
tivity of their detection by real-time PCR. We also explored the
efficacy of using SNP assays to measure chimerism. Each PCR reac-
tion includes two primer/fluorescent probe pairs to allow genotyping
of the two possible variants at the SNP site in a target template
sequence. We found that both the polymorphic nucleotide as well
as the sequence immediately adjacent to the polymophism influences
the ability to distinguish a signal between the target and mismatched
sequences. Moreover, the specific fluorescent reporter probe can
affect the difference in signal intensity between the target and mis-
matched sequences which determines the specificity of the assay.
By optimal selection of the polymorphic sequences and fluorescent
reporter, the real-time PCR SNP assay of chimerism can attain a
sensitivity of 0.1%–0.5%with nearly 100% specificity. This strategy
will be applied in upcoming clinical trials of bone marrow cell
therapy.
XC and TJH contributed equally to this work272
IMPACT OF CYTOGENETICS AND MARROW REMISSION STATUS ON
DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
(AML) OR MYELODYSPLASTIC SYNDROME (MDS) UNDERGOING ALLO-
GENEIC STEM CELL TRANSPLANTATION
Koca, E., Saliba, R.M., de Lima, M., Popat, U., Kebriaei, P., Rondon, G.,
Zhang,W., Giralt, S., Andersson, B.A., Champlin, R. University of Texas
MD Anderson Cancer Center, Houston, TX
Our aim was to determine the impact of cytogenetics and remis-
sion status on outcome of AML orMDS pts treated with allogeneic
stem cell transplantation (alloSCT) conditioned with busulfan
(Bu) based regimens. We reviewed retrospectively all pts who re-
ceived alloSCT at MD Anderson Cancer Center for AML or
MDS between 1990 and 2007 conditioned with Bu (1 mg/kg IV
q 6h 4 days) and cyclophosphamide (60 mg/kg IV  2 days),
Bu and fludarabine (Flu) in myeloablative (Bu 130 mg/m2 4
days and Flu 40 mg/m2 4 days) or reduced intensity doses. Pts
in first or subsequent remission and those achieving morphologic
remission after initial induction treatment but without platelet re-
covery to .100,000/mcl (marrow remission) were included in the
analysis. Pts were categorized according to the Dana-Farber cyto-
genetics classification. Cox’s regression analysis was used to evalu-
ate prognostic factors for disease progression, overall survival (OS)
and progression free survival (PFS). Among 265 pts (median age 45
[5–69]) diagnoses were AML (n 5 217), MDS (n 5 17) and AML
evolving from MDS (n 5 31). Disease status at alloSCT was; first
complete remission (CR) (n 5 129), advanced remission (beyond
first CR) (n 5 93) and marrow remission (n 5 43). Majority of
the donors were matched related (n 5 152) or matched unrelated
(n 5 94). Stem cell source was bone marrow (n 5 108), peripheral
blood (n 5 153) or cord blood (n 5 4). Median follow-up time of
surviving pts was 39 months (1.6–189). The 3 years actuarial prob-
ability of OS was 55% and PFS 49%. On univariate analysis, ad-
verse cytogenetics were associated with higher disease
progression rate (p\0.05). There was also a trend for worse OS
(p 5 0.09) and PFS (p 5 0.098) for adverse cytogenetics. In addi-
tion pts in ‘‘marrow remission’’ compared to those who were in CR
with full platelet recovery prior to transplant had a significantly
higher rate of disease progression (p 5 0.001) and poorer 3 years
OS (37% vs 59%, p 5 0.001) and PFS (30% vs 53%, p 5 0.001).
Outcomes were comparable for pts in first and advanced remis-
sions. Pts with de novo AML had more favorable OS (p 5 0.02)99
100 Poster Session-IIand PFS (p 5 0.05). On multivariate analysis, pts who were in
‘‘marrow remission’’ and had adverse cytogenetics had a signifi-
cantly higher rate of disease progression (p\0.001), lower OS
(p\0.001), and lower PFS (p\0.001). De novo AML was associ-
ated with a significantly better OS and PFS. Cytogenetics and
remission status are significant predictors for outcomes after
alloSCT in pts with AML or MDS.273
A STRATEGY FOR REDUCING CD31 CONTENT OF PERIPHERAL BLOOD
PROGENITOR CELL PRODUCTS FOR MATCHED RELATED DONOR ALLO-
GRAFTS
Racquel, I.-S.D., Khaleel, A., Arabella, T., Larry, L., William, V.P.,
Donna, S.E. University of Alabama, Birmingham, AL
Acute GVHD (aGVHD) causes significant morbidity and mor-
tality after allogeneic stem cell transplantation. Stem cells col-
lected from the peripheral blood (PBSC) provide greater ease of
cell collection and faster engraftment vs marrow source stem cells.
The association of PBSC with faster engraftment is likely due to
a higher number of committed precursors in the PBSC product.
Unfortunately, PBSC grafts are associated with an increased inci-
dence and severity of aGVHD due to higher numbers of alloreac-
tive T cells. Compensatory survival benefit of the larger CD31
content in PBSC collections resulting from graft vs malignancy ef-
fect has been difficult to demonstrate, however significant ‘‘purg-
ing’’ of CD31 cells below the CD31 content of marrow source
allograft results in engraftment failure, and disease relapse. We
hypothesize that reducing CD31 cell content of PBSC grafts
that of marrow source grafts would decrease the incidence of
aGVHD without compromising engraftment. We recently re-
ported a retrospective analysis of 98 patients who received
PBSC product purged of T cells in vivo by the administration of
dexamethasone to the donor for the last 3 days of G CSF mobili-
zation. The mean CD31 and CD341 cells collected were 3.68 
108 cells/kg (sd5 2.27 108) and 8.82 106 cells/kg (sd5 5.05
106) respectively. All patients engrafted successfully and had less
acute GVHD than historical controls (19% grade II–IV at 100
days). Updated data includes 41 additional patients who achieved
comparable T cell depletion with a mean CD31 content of 3.38
107 cells/kg (sd 5 2.19  107) and mean CD 341 content of
6.98  106 cells/kg (standard deviation of 4.05  106). However,
like almost all previous studies, the CD31 content of the grafts
is highly variable. We are now conducting a phase II non-random-
ized trial under an IDE from the FDA standardizing the T cell
content of the donor PBSC product to 2.5 60.5  10 7 cells/kg,
the concentration found in marrow collections. After setting aside
a portion of the PBSC product containing 2.5 60.5  107, the re-
maining product is CD31 cell depleted using magnetic bead cell
sorting technology. This allows us to study the influence of CD31
subsets, NK cells, and other graft components in engraftment, im-
mune reconstitution, and GVHD risk. Ultimately the goal of
standardization is to create a platform for ‘‘add back’’ research
and permitting a prescriptive approach to optimizing graft
content for different clinical situations.274
PERSONALIZED DOSING OF CYCLOPHOSPHAMIDE IN THE TOTAL
BODY IRRADIATION-CYCLOPHOSPHAMIDE CONDITIONING REGIMEN:
A PHASE II TRIAL IN PATIENTS WITH HEMATOLOGIC MALIGNANCY
McDonald, G.B., Guthrie, K.A., Batchelder, A., Witherspoon, R.,
McCune, J.S. Fred Hutchinson Cancer Research Center, Seattle, WA
Total body irradiation and cyclophosphamide (CY) conditioning
may cause regimen-related toxicity and mortality because of highly
variable metabolism of CY. Themetabolite carboxyethylphosphor-
amide mustard (CEPM) is a reporter molecule for toxins derived
from CY. We tested the hypothesis that personalized CY dosing
would result in less liver and kidney toxicity, compared to
weight-based CY dosing (2  60 mg/kg), without affecting the
relapse rate.
Methods:We personalized the dose of CY for 50 patients receiv-
ing TBI 12 Gy using therapeutic drug monitoring with Bayesianparameter estimation after the first CY dose, to adjust the second
CY dose before allogeneic transplant (Clin Cancer Res
2006;12:4888–98). The target exposure to CEPM was 325 6 25
mM$hr. Concurrent allograft patients (N 5 100) who were condi-
tioned with TBI 12 Gy and CY 120 mg/kg served as controls.
Study endpoints were peak bilirubin levels, acute kidney injury
(doubling baseline Cr), and relapse/survival using proportional
hazards regression models.
Results: All patients on a personalized CY dosing protocol
received a first CY dose of 45 mg/kg. The mean second CY dose
was 66 mg/kg (range, 0–100 mg/kg), and the mean total CY dose
was 111 mg/kg (range, 45–145 mg/kg). There were 15 patients
whose total CY dose exceeded 120 mg/kg. The mean total AUC-
CEPM was 302 mM$hr (median 301, range 136–442 mM$hr).
The average percent deviation of the observed AUC-CEPM
from our target of 325 mM$hr was -7%. Peak total bilirubin was
significantly lower with personalized CY dosing than with stan-
dard dosing (median 1.3 mg/dL, range 0.7 – 8.8) vs. 1.7 mg/dL,
range 0.4 – 18.3), p 5 0.03. The hazard of kidney injury was re-
duced by 38% with personalized CY dosing (p 5 0.03); high bili-
rubin levels were associated with kidney injury (p 5 0.003).
Despite a lower total CY dose for most patients, personalized
CY dosing was not associated with worse relapse or survival out-
comes for the study cohort as a whole, or when analyzed as sub-
groups (by myeloid vs. lymphoid malignancy and by risk of
relapse after transplant).
Conclusions: Bayesian therapeutic drug monitoring and person-
alized CY dosing reduces extreme variability in CY metabolism in
the TBI/CY regimen, resulting in less liver and kidney injury,
compared to standard CY dosing, with no difference in relapse or
survival.275
PROSPECTIVE RANDOMIZED STUDY COMPARING NON MYELOABLA-
TIVE (FLU-TBI) AND REDUCED INTENSITY (FLU-BU-ATG) CONDITION-
ING FOR HEMATOLOGICAL MALIGNANCIES: A MULTICENTER ITAC
STUDY
Blaise, D.1, Furst, S.1, Bay, J.O.2, Faucher, C.1, Michallet, M.3,
Boiron, J.M.4, Cahn, J.Y.5, Mohty, M.6 1 Institut Paoli-Calmettes, Mar-
seille, France; 2Centre Jean Perrin, Clermont Ferrand, France; 3Hopital
Edouard Herriot, Lyon, France; 4EFS Aquitaine Limousin, Bordeaux,
France; 5CHU, Grenoble, France; 6Hotel Dieu, Nantes, France
Reduced intensity conditionings (RIC) have been introduced 10
years ago. However no definitive data exist defining the optimal
myeloablative and/or immunosuppressive association. We report
the first prospective comparison between 2 popular regimens based
on reduced intensity or non-myeloablative approaches. Flu-
Bu-ATG (Study A) associated Fludarabine (30mg/m2/5 days),
Oral Busulfan (8 mg/kg over 2 days) and Thymoglobuline (2.5
mg/m2/1day). Fluda-TBI (Study B) consisted of Fludarabine
(25mg/m2/ 3 days) and 2 Gy TBI. This program included two ran-
domized phase 2 clinical trials according to a phase 2 selection de-
sign (Liu, 1993 and 2001). Primary endpoint was one-year overall
survival (OS). Stopping rules included excessive engraftment fail-
ure and transplant related mortality ratio. Inclusion criteria were
patients presenting a hematological malignancy, non eligible for
myeloablative allo SCT, aged between 18 and 65, with a suitable
HLA identical sibling. First patient was included in January
2003. A total of 144 patients were randomized, and 137 patients
(Group A: N 5 71; group B: N 5 66) were documented in the da-
tabase for this abstract. In all, groups were well balanced for patient
characteristics; Median age 55 (32–66); Male gender: 63%; Diag-
nosis: acute leukemia: 18%; NHL: 23%; MM: 41%; Others:
18%; Disease status: CR5 29%; PR and stable disease5 63%; re-
fractory disease: 8%. Graft failure were documented in 4 patients in
group B. Cumulative incidence (CI)of aGVHD and cGVHD were
respectively of 24.4% (Group A 29.5%; Group B 19.4%) and
75.2% (Group A 77.8%; Group B 72.5%). One year TRM CI
was 18% (11–25)(Group A: 22% (11–33): group B: 15% (6–24);
p 5 NS). Overall 56% patients were alive at time of abstract
(Group A: 49%; Group B: 62%: p 5NS) for a one-year OS prob-
ability estimate of 0.75 [0.66 – 0.82] (Group A 0.73 [0.59 – 0.82];
Group B 0.78 [0.64 – 0.86]). In conclusion, this study establishes
